News

Patients on lasmiditan had 3.8–7.2 times greater odds of achieving pain freedom at 2 hours compared to placebo in at least 2 out of 3 migraine attacks.

Here's what is coming soon to NeurologyLive.

The director of the Mid-Atlantic Epilepsy and Sleep Center in Bethesda, Maryland, discussed whether certain epilepsy populations were affected greater by the COVID-19 pandemic.

The multinational data revealed a risk of stroke of 0.5%, with the need for mechanical ventilation and the presence of ischemic heart disease being the most predictive indicators of stroke.

Neurology News Network for the week ending October 10, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 9, 2020.

The investigators noted that their results can be replicated independently in a real-world cohort, they may have clinical implications for daily practice.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Costantino Iadecola, MD.

The professor of neurology and pediatrics at the University of Alabama at Birmingham Epilepsy Center provided insight on the importance of treating TSC early, and how far away we are from prevention.

Phase 2 results demonstrated proof-of-concept for treatment with neflamapimod, suggesting the need for a phase 3 study in the coming future.

Singer and former GLEE cast member Noah Guthrie will be featured during the 1-day event.

Data from a long-term phase 2 study in episodic migraine suggest that those treated with erenumab maintain reductions in both monthly migraine days and use of acute migraine medications in the long-term.

The director of Laryngology Research at Mass Eye and Ear spoke to the use of machine learning programs to aid physicians in the diagnosis of dystonia.

The upcoming phase 2b/3 study of mesdopetam in patients with Parkinson disease is set after the results of previous successful phase 1, phase 2a, and phase 2 studies.

The 5-year grant will support a research project that will use biomarkers to develop a predictive mathematical model to identify specific individuals with Parkinson disease who may develop dementia.

Patients treated with Axovant’s gene therapy AXO-Lenti-PD reported improvements of 40% in UPDRS-III scores, and 71% improvement in activities of daily living.

Nearly two-thirds of patients achieved developmental motor milestones not observed in the natural history of SMA Type 1 at a mean duration of follow-up of 10.6 months.

Sucheta M. Joshi, MD, MS, and Nicholas Beimer, MD, outline how EpiTRAQ may be incorporated in future studies and what outcomes may be observed.

James Leverenz, MD, director of the Lou Ruvo Center for Brain Health at Cleveland Clinic, discussed the strides made in Alzheimer disease research and the importance of diversity in research populations.

Linear mixed effects models revealed that anticholinergic medications predicted a steeper slope of decline in memory and language with effects exacerbated in individuals with Alzheimer disease risk factors.

The postdoctoral research fellow in the Dystonia and Speech Motor Control Laboratory at Mass Eye and Ear spoke to the clinical translation of the AI-based DystoniaNet tool.

Results from a 24-week phase 2a trial and its 2-year extension suggest that patients taking vamorolone experienced motor outcome improvements compared to corticosteroid-naïve individuals.

The initiative, funded by Jazz, will include educational multimedia content such as a series of podcasts with expert interviews discussing sleep and related disorders.

The director of Laryngology Research at Mass Eye and Ear discussed how the AI-based DystoniaNet came to be and what challenges impact the diagnosis of dystonia.

The Clinical Global Impression of Change and Caregiver Global Impression of Change scores suggest improvements extending beyond motor seizure frequency reduction in both patients with CDD and Dup15q.

Julio J. Fernandez-Mendoza, PhD, a clinician-scientist at Penn State Hershey Sleep Research & Treatment Center, of Penn State Health, spoke to the implications of a recent study he and colleagues conducted.

Advanced imaging shows Parkinson disease can begin as brain-first or body-first.

Here's what is coming soon to NeurologyLive.

Solid Biosciences noted that its response to the agency requests for further information about manufacturing as well as updated safety and efficacy data on all dosed patients led to the lift.

The director of the Parkinson’s Foundation Center for Excellence at the University of Kansas Medical Center provided insight on the lapses in levodopa-carbidopa treatment and what potential changes could come in the future.